Eslam M - Search Results

1

Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.

Tang LJ, Sun DQ, Song SJ, Yip TC, Wong GL, Zhu PW, Chen SD, Karsdal M, Leeming DJ, Jiang P, Wang C, Chen Q, Byrne CD, Targher G, Eslam M, George J, Wong VW, Zheng MH. Tang LJ, et al. Among authors: eslam m. Liver Int. 2024 May;44(5):1129-1141. doi: 10.1111/liv.15878. Epub 2024 Mar 1. Liver Int. 2024. PMID: 38426611

2

Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?

Eslam M, George J. Eslam M, et al. Hepatol Int. 2015 Jan;9(1):5-8. doi: 10.1007/s12072-014-9600-2. Epub 2014 Dec 20. Hepatol Int. 2015. PMID: 25788373 No abstract available.

3

Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution.

Eslam M, George J. Eslam M, et al. Semin Liver Dis. 2015 Nov;35(4):402-20. doi: 10.1055/s-0035-1567830. Epub 2015 Dec 16. Semin Liver Dis. 2015. PMID: 26676815 Review.

4

Genetic and epigenetic mechanisms of NASH.

Eslam M, George J. Eslam M, et al. Hepatol Int. 2016 May;10(3):394-406. doi: 10.1007/s12072-015-9689-y. Epub 2015 Dec 18. Hepatol Int. 2016. PMID: 26683320 Review.

5

The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.

Kazankov K, Barrera F, Møller HJ, Rosso C, Bugianesi E, David E, Younes R, Esmaili S, Eslam M, McLeod D, Bibby BM, Vilstrup H, George J, Grønbaek H. Kazankov K, et al. Among authors: eslam m. Liver Int. 2016 Oct;36(10):1549-57. doi: 10.1111/liv.13150. Epub 2016 May 12. Liver Int. 2016. PMID: 27102725

6

Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans.

Asimakopoulos A, Mangia A, Dore GJ, Lloyd AR, George J, Eslam M. Asimakopoulos A, et al. Among authors: eslam m. Hepatology. 2016 Dec;64(6):2264-2265. doi: 10.1002/hep.28626. Epub 2016 Jun 27. Hepatology. 2016. PMID: 27121959 No abstract available.

7

Targeting IFN-λ: therapeutic implications.

Eslam M, George J. Eslam M, et al. Expert Opin Ther Targets. 2016 Dec;20(12):1425-1432. doi: 10.1080/14728222.2016.1241242. Epub 2016 Oct 11. Expert Opin Ther Targets. 2016. PMID: 27681264 Review.

8

The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.

Thabet K, Chan HLY, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML, Wong VW, Nazmy M, Fischer J, Liddle C, George J, Eslam M. Thabet K, et al. Among authors: eslam m. Hepatology. 2017 Jun;65(6):1840-1850. doi: 10.1002/hep.29064. Epub 2017 Apr 28. Hepatology. 2017. PMID: 28109005 Free article.

9

Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study.

Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, Porzio M, Rosso C, Fargion S, George J, Craxì A. Petta S, et al. Among authors: eslam m. Liver Int. 2017 Sep;37(9):1389-1396. doi: 10.1111/liv.13397. Epub 2017 Mar 13. Liver Int. 2017. PMID: 28235154 Free article.

10

TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.

John M, Metwally M, Mangia A, Romero-Gomez M, Berg T, Sheridan D, George J, Eslam M. John M, et al. Among authors: eslam m. Gastroenterology. 2017 Nov;153(5):1448-1449. doi: 10.1053/j.gastro.2017.04.056. Epub 2017 Oct 6. Gastroenterology. 2017. PMID: 28993163 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

172 results

Search Page